Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.
Clinical trial NCT06523231 · COMPLETED
Trial details
- NCT number
- NCT06523231
- Sponsor
- LimmaTech Biologics AG
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-07
- Primary completion
- 2025-08-27
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.